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the consortium. The brochure “Conclusions and Recom-
mendations” is neither a scientific report nor a comprehen-
sive assessment paper and was never claimed to be such a 
document. At this stage, it is important to recall that one of 
the central objectives of the GRACE project was to conduct 
animal feeding trials and in vitro studies to compare the 
added value of 90-day feeding trials of whole GM food/feed 
with that of advanced state-of-the-art analytical, in vitro and 
in silico tools by making use of the genetically modified 
MON810 maize as test material. In no case was the GRACE 
project consortium requested to perform a full risk assess-
ment on the GM maize MON810, and none of the scientific 
documents published by the GRACE project consortium as 
well as the brochure “Conclusions and Recommendations” 
were considered to replace a full risk assessment of the GM 
maize MON810. The mandatory character of the 90-day 
animal feeding trial with whole GM food/feed in the Imple-
menting Regulation (EU) No. 503/2013 assumes that its 
performance generally and per se reduces the level of uncer-
tainty. Our trials with the GM maize MON810 have shown 
that this untargeted approach does not achieve an added 
value. In the context of the “Guidance on Uncertainty in 
EFSA Scientific Assessment” (EFSA Scientific Committee 
2016), it is unlikely that such untargeted feeding trials can 
generally and substantially support the uncertainty analyses 
of an assessment question as well as the decision making.
Regarding the issue of uncertainty analyses raised by our 
Austrian colleagues, we interpret the paper by the EFSA 
Scientific Committee (2016) as a guideline targeting the 
handling of (risk) assessment questions rather than single 
studies. Nevertheless, EFSA refers to uncertainty analyses 
in its guidance document published in 2011 (EFSA 2011): 
“A specific chapter on assumptions and uncertainty analy-
sis should be included in the study report. Any uncertain-
ties (in addition to natural variation in biological endpoints) 
We thank our Austrian colleagues for entering into an open 
discussion on the contentious topic regarding the necessity of 
animal feeding trials with whole genetically modified (GM) 
food/feed based on the outcome of the EU-funded project 
GRACE. We agree that an evidence-based and thorough sci-
entific discussion should precede any far-going decision on 
mandatory trials to be used in the risk assessment of whole 
GM food/feed to prevent undermining its scientific soundness.
Woegerbauer et al. (2016) refer to the brochure “Conclu-
sions and Recommendations” (GRACE 2015a), which was 
published on the website of the project, and, specifically, to 
“PART I: Conclusions and recommendations on animal feed-
ing studies and alternative approaches with regard to Article 
12, Implementing Regulation (EU) No. 503/2013” therein.
Hereby we answer to the different points raised by 
Woegerbauer et al. (2016) as follows:
(1)  “…it is astonishing that in this final report the GRACE 
consortium appears to have refrained from communi-
cating uncertainties…”
Answer To clarify this issue on which Woegerbauer et al. 
(2016) have placed special emphasis, it should be noted 
that the brochure “Conclusions and Recommendations” 
summarizes the experiences and opinions of the GRACE 
project consortium by listing central statements and high-
lights key issues for discussion from the point of view of 
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in the design of the experimental model which might influ-
ence the power of the experiment should be highlighted 
and quantified as far as possible. The assumptions underly-
ing the statistical analysis should be reported and tested for 
robustness.” We are of the opinion that the complete data 
sets as well as the detailed description of the trials and the 
obtained results provided with the scientific publications, 
each of them including a detailed statistical report with 
an explanation regarding the statistical models used, suffi-
ciently display the trial-specific uncertainties.
In addition, the final report on the stakeholder con-
sultations “Assessing Feeding Studies and Alternative 
Approaches for GMO Risk Assessment” (GRACE 2015b) 
is available at the GRACE project website (www.grace-
fp7.eu) and lists in detail questions and answers regarding 
the performances of the feeding trials. This comprehensive 
pool of information is provided to help assessors, decision 
and policy makers to evaluate the added value of animal 
feeding trials with whole GM food/feed, and the “Conclu-
sions and Recommendations” brochure depicts the inter-
pretation of the findings by the GRACE project consortium.
(2)  “…we miss a clearly structured description of the 
‘strengths and limitations’ of 90-day feeding trials in 
rodents and alternative studies as announced in the 
introductory section of the final ‘Conclusions and 
Recommendations’ (GRACE Consortium 2015).”
Answer The GRACE project consortium stated that 
GRACE aims “to provide recommendations on the appro-
priateness of these tools for the risk assessment of GM 
crops by considering the scientific strengths and limita-
tions of the different approaches” (GRACE 2015a). Dur-
ing the elaboration of the brochure “Conclusions and Rec-
ommendations,” the scientific strengths and limitations of 
the different approaches were thoroughly considered and 
discussed at a workshop held on the 7th and 8th of Octo-
ber 2015 in Vienna (see point 3 and GRACE 2015b). Due 
to the focus of the brochure “Conclusions and Recom-
mendations,” as described in the answer to point 1, not 
all strengths and limitations accompanying the respective 
approaches have been listed.
(3)  “Although stakeholder involvement is emphasized 
on several occasions in the booklet, GRACE refrains 
from reporting any discrepancies which had arisen 
during extended oral and written discussions on the 
project design and on the interpretation of the results.”
Answer Stakeholders were actively involved in the dis-
cussions on the project design, the interpretation of the 
results as well as the elaboration of the project conclusions 
and recommendations. This active stakeholder involvement 
is documented by the following consultation reports, all of 
them having been published (i.e., being publicly available):
(a) GRACE Stakeholder Consultation on animal feeding 
studies and in vitro studies in GMO risk assessment, 
March 2013 (GRACE 2013a).
(b) Responses of GRACE team members to questions and 
comments raised by stakeholders, December 2013. 
Addendum to the Stakeholder Consultation Report 
published in March 2013 (GRACE 2013b).
(c) GRACE Stakeholder Consultation on animal feed-
ing studies in GMO risk assessment: Chronic toxicity 
(1-year) study and subchronic toxicity and longitudinal 
metabolomics study and responses of GRACE team 
members to questions and comments raised by stake-
holders, July 2014 (GRACE 2014).
(d) Draft results of the 90-day animal feeding studies and 
progress of the in vitro, in silico and analytical studies 
with GM maize, June 2015 (GRACE 2015c).
• Raw data were provided to those participants that 
signed a non-disclosure agreement.
(d) Stakeholder Consultation on the results of the GRACE 
feeding studies as well as of the in vitro, in silico and 
analytical studies and on general conclusions and rec-
ommendations, November 2015 (GRACE 2015b).
• Raw data were provided to those participants that 
signed a non-disclosure agreement.
Finally, draft conclusions and recommendations were 
provided by the GRACE project consortium for discussion 
during a workshop held on the 7th and 8th of October 2015 
in Vienna (GRACE 2015a). All stakeholder responses, 
either provided during the workshop or submitted in writ-
ing, were considered during their finalization. GRACE 
responses to the comments are thoroughly documented in 
the corresponding consultation report (GRACE 2015b).
(4)  “Limitations and weaknesses of the overall study 
approach (e.g. testing of only a single active principle; 
no empirical analysis of stacked events or GMOs with 
complex alterations of metabolic pathways or events 
coding for different modes of action etc.) are not 
clearly communicated.”
Answer The Implementing Regulation (EU) No. 
503/2013 does not suggest a hierarchical and targeted 
assessment process prior to the performance of 90-day feed-
ing trials with whole GM food/feed. It generally assumes 
that the approach reduces uncertainty and increases the 
confidence of the consumers. The feeding trials performed 
by GRACE demonstrated that this assumption does not 
generally hold true and this is in particular the case if there 
is no previous indication of a potential adverse effect by 
other approaches. So far, it has not been shown that rodent 
feeding trials are a sensitive test system to identify adverse 
effects induced by whole GM food/feed and that they are 
more sensitive than other available methods. The limita-
tions of the approach have not only been demonstrated by 
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the GRACE project but also, e.g., by analyzing GM pota-
toes with an altered glycoalkaloid spectrum (Langkilde 
et al. 2012). Therefore, the GRACE team suggested to fol-
low an overall approach that is based on the identification of 
triggering findings (e.g., by a detailed analysis of the plant 
material composition), which in turn may justify an animal 
feeding trial with whole GM food/feed. A priori and without 
a case-specific consideration—e.g., with regard to a com-
plex alteration of metabolic pathways—rodent feeding trials 
with whole GM food/feed do not provide an added scientific 
value for the risk assessment of GM crops.
(5)  “The ‘Conclusions and Recommendations’ imply gen-
eral validity for the toxicological assessment of plant-
derived GMOs but the project design was not intended 
to provide experimental evidence in support of these 
generalizations. ‘GRACE is expected to provide sound 
conclusions and recommendations on the adequacy of 
the approaches tested in the frame of GRACE’ … and 
… is in the position to report results and conclusions 
on experience gained with MON810. But GRACE 
extrapolates far beyond this scope. This constitutes a 
bias which should be clearly communicated to the risk 
managers in the respective booklet as this is the basis 
for informed decision making.”
Answer See answer to point 4.
(6)  “GRACE highlights the importance of a ‘targeted and 
testable hypothesis’ as trigger for animal experiments 
but does not communicate that unintended effects may 
be - in certain cases - unpredictable and unexpected 
and, thus, might not be detectable by a hypothesis-
driven approach.”
Answer The detection of unpredictable effects should 
indeed be based on screening methods of considerable sen-
sitivity. Rodent feeding trials with whole GM food/feed 
performed according to the OECD Test Guidelines, in con-
trast to those with chemicals, have failed to demonstrate 
this degree of sensitivity (see, e.g., Langkilde et al. 2012).
(7)  “In our opinion the selection of certain project partners 
was not as optimal as would have been required by the 
demanding specific conditions related to toxicity test-
ing of GMOs in whole food and feed. In particular the 
animal experimentation indicates some flaws which 
might have been relevant for the explanatory power 
of the results as a whole: The observation of circadian 
effects during trial A and trial B … might be indicative 
for a non-optimal execution of these experiments, as 
this kind of effect would not have emerged if the stud-
ies were performed exactly according to OECD TG 
408, EFSA 2011, and GLP requirements (EFSA 2011; 
OECD 1998).”
Answer The European Commission required in the pro-
ject formulation and negotiation phases that the feeding tri-
als should be performed in an institution not being involved 
before in the commercial testing of whole GM food/feed to 
avoid any kind of conflicting interests. It has to be pointed 
out that the Laboratory of Toxicology of the Slovak Medi-
cal University has a long-lasting experience in the perfor-
mance of 90-day subchronic toxicity studies with pesticides 
and was chosen by the GRACE project consortium because 
of this expertise. In the frame of GRACE, the Slovakian 
colleagues successfully performed four 90-day feeding tri-
als and a 1-year feeding study, and in no case were there 
any indications that they were not able to cope with the 
feeding trials as well as the subsequently performed blood 
and urine analyses. It is important to note that none of the 
parameters measured according to the OECD TG 408 in the 
90-day feeding trials A and B were affected by the circa-
dian rhythm of the animals. The influence of the circadian 
rhythm on the omics data underlined the need for a targeted 
adjustment of the study design when—in addition to a 
routine toxicological feeding trial according to the OECD 
TGs—additional methods that track physiological dynam-
ics are applied. Hence, the statement by Woegerbauer et al. 
(2016) that “this kind of effect would not have emerged if 
the studies were performed exactly according to OECD TG 
408, EFSA 2011, and GLP requirements” is misleading in 
more than one way as, e.g., a randomized sampling during 
necropsy is not suggested by the corresponding documents. 
The 90-day feeding trials were performed under GLP con-
ditions by taking into account the OECD TG 408 as well 
as the EFSA recommendations (those parts that were not 
performed under GLP conditions are explicitly mentioned 
in the corresponding study plan). We are of the opinion that 
discrediting the Slovakian colleagues that performed the 
animal feeding studies in the frame of the GRACE project 
on a high technical and scientific level conflicts with a fair 
scientific debate.
(8)  “The necessity to include conventional control maize 
varieties (2 of them contaminated with MON810) 
as surrogates for missing historical control data is 
another indication for a non-optimal expertise on this 
type of whole food/feed studies in rodents.”
Answer The inclusion of conventional maize varieties 
as surrogates for missing historical control data is explic-
itly recommended by EFSA (EFSA Scientific Committee 
2011) and is in no way related to the expertise of an ani-
mal housing facility to perform 90-day subchronic toxicity 
studies. A statement regarding the expertise of the Labora-
tory of Toxicology of the Slovak Medical University, which 
performed four 90-day feeding trials and a 1-year feeding 
study with diets containing the GM maize MON810 in the 
frame of the GRACE project, is included under point 7.
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(9)  “A trend analysis considering trends and patterns in 
statistically non-significant differences (taking into 
account all applied diets, but not disregarding the pri-
mary importance of the comparison of GM and non-
GM near-isogenic control groups) is missing although 
this approach would provide valuable information.”
Answer The results of the descriptive statistical analyses 
revealed no trends that would have justified a further analy-
sis. Any interested party can view these analyses in form 
of statistical reports for the already published 90-day feed-
ing trials A and B and the 1-year feeding trial with the GM 
maize MON810 on the website www.cadima.info. Moreo-
ver, the freely available data sets enable any third party to 
run their own analyses.
(10)  “In support of its conclusions GRACE refers on sev-
eral occasions to the CADIMA database and to (envi-
sioned) scientific publications (GRACE Consortium 
2015). At the time of writing the CADIMA database 
was not fully functional and contained only the data 
from trial A and B… However, it is questionable 
whether a database lacking a substantial part of the 
project results and unpublished papers are the appro-
priate basis for risk managers to decide in a timely 
manner on possible amendments of Commission 
Implementing Regulation 503/2013 …”
Answer The GRACE project consortium decided from 
the beginning to publish the results of the feeding trials in 
form of papers in an internationally recognized scientific 
journal and to provide open access to the detailed feeding 
trial data in the CADIMA database after acceptance of the 
manuscripts. In this context, it is important to note that, as 
already indicated under point 3, stakeholders had access to 
the raw data of the feeding trials before the corresponding 
publication of the manuscripts if they signed a non-disclo-
sure agreement. The peer review of the very detailed manu-
scripts turned out to be considerably time-consuming, but in 
the meantime the outcome of the first two 90-day feeding 
trials A and B (Zeljenková et al. 2014), the outcome of the 
1-year feeding trial (Zeljenková et al. 2016) and the descrip-
tion of the statistical methods used to analyze the data 
obtained in the feeding trials (Schmidt et al. 2016a) have 
been published in Archives of Toxicology. As promised, now 
that the papers have been published, the corresponding data 
sets can be downloaded on the website https://www.cadima.
info/index.php/area/publicAnimalFeedingTrials. Hence, the 
risk assessors do have all the data they need to decide on the 
future of the Implementing Regulation (EU) 503/2013. A 
manuscript reflecting the results of all 90-day feeding trials 
conducted in GRACE and including the description of the 
last two 90-day feeding trials performed (the so-called feed-
ing trials D and E) very recently has been accepted for pub-
lication in Archives of Toxicology (Schmidt et al. 2016b).
(11)  “GRACE applied two conventional control maize vari-
eties which were contaminated with MON810 in fact 
constituting GM diets with a GM content of approx. 
1 % (Zeljenková et al. 2014). According to the European 
GMO legislation currently in force these diets would 
have had to be labelled as being genetically modified 
(European Commission 2003). So it is at least question-
able whether these contaminated varieties are eligible to 
establish historical control data which should be manda-
torily generated by non-GM lines (EFSA 2011).”
Answer First of all, the decision to label plants and 
products thereof containing more than 0.9 % of a GM 
organism (European Commission 2003) as being geneti-
cally modified is a political one and in no way indicates 
adverse effects. Moreover, Woegerbauer et al. (2016) men-
tion that the diet containing the conventional 1 maize vari-
ety (PR33W82) used in the 90-day feeding trials A and B 
was contaminated with GM MON810 at a level of approx. 
1 %, but they do not mention that: (1) GM maize MON810 
was not detected in the diet containing the conventional 2 
maize variety (SY-NEPAL); (2) the 13 hematology and 15 
clinical biochemistry parameters measured in the blood of 
rats being fed the control, conventional 1 and conventional 
2 diets were, with single exceptions, comparable. Taken 
together, even at a contamination level of 1 % MON810 the 
rat groups being fed conventional maize-containing diets 
are eligible to establish historical control data.
Woegerbauer et al. (2016) allude to an electronic annex 
to their Letter to the Editor, in which a number of further 
concerns are listed and which has been published on the 
GRACE homepage. The GRACE consortium will answer 
to all the issues raised in the above-mentioned electronic 
annex in due time.
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